Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
Pooled result · Thyroid cancerResult — go to the resultPooled weighted hazard ratio 0.81 CI 0.59–1.12Authors' conclusion
In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs.
Study context
- Population
- Patients with T2D between 2007 and 2023, six population-based databases from Canada (Ontario), Denmark, Norway, South Korea, Sweden and Taiwan6 databases
- Participants
- 98,147 vs 2,488,303
- Comparison
- GLP-1 RA vs DPP-4i
- GLP1-RAn = 98,147
- DPP-4in = 2,488,303reference
- Outcome
- Thyroid cancer
- Follow-up
- Median among GLP1-RA users 1.8 to 3.0 years
Methodological detailspopulation-based databases from 6 countries, standardized mortality ratio weights from time-specific propensity scores, fixed-effects pooling, Subgroup analysis of types of thyroid cancer was not possible
- Population-based databases from 6 countries
- Standardized mortality ratio weights from time-specific propensity scores
- Fixed-effects pooling
- Subgroup analysis of types of thyroid cancer was not possible
Pooled result
As reported in the abstract
Pooled weighted hazard ratio
0.81
CI 0.59–1.12
GLP1-RAvs DPP-4i
pooled weighted HR 0.81 (CI 0.59–1.12)
Further pooled results
Thyroid cancer by cumulative GLP-1 RA dose (ever-users)
- No increased risk of thyroid cancer with increasing cumulative dose of GLP1-RA
Supplementary analyses
- Results remained consistent across a range of supplementary analyses
Original publication
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study. Thyroid. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →